Cancer and venous thromboembolism

American Heart Journal

Volumn 132, Issue 4, 1996, Pages 850-855

  Piccioli, Andrea ^a   Prandoni, Paolo ^a   Ewenstein, Bruce M ^b   Goldhaber, Samuel Z ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; FIBRINOPEPTIDE A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; THROMBIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD VESSEL INJURY; CANCER; HUMAN; HYPERCOAGULABILITY; ORAL DRUG ADMINISTRATION; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOSIS; THROMBOEMBOLISM; VEIN THROMBOSIS; VENOUS STASIS;

EID: 0029910003     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90321-X     Document Type: Article

References (50)

1. Trousseau A. Phlegmasia alba dolens. Clinique medicale de l'hotel-dieu de Paris. Paris: J-B Balliere et Fils, 1864;3:654-712.
2. Nordström M, Lindblad B, Anderson H, Bergqvist D, Kjellström T. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ 1994;308:891-4.
3. Francis JL, Carvalho M, Francis DA. The clinical value of tissue factor assays. Blood Coagul Fibrinolysis 1995;6:S37-44.
4. Kubota T, Andoh K, Sadakata H, Tanaka H, Kobayashi N. Tissue factor released from leukemic cells. Thromb Haemost 1991;65:59-63.
5. Francis JL. Haemostasis and cancer. Med Lab Sci 1989;46:331-46.
6. Falanga A, Alessio MG, Donati MB, Barbui T. A new procoagulant in acute leukemia. Blood 1988;71:870-5.
7. Gordon SG, Benson B. Analysis of serum cancer procoagulant activity and its possible use as a tumor marker. Thromb Res 1989;56: 431-40.
8. Scates SM. Diagnosis and treatment of cancer-related thrombosis. Semin Thromb Hemost 1992;18:373-9.
9. Lorenzet R, Peri G, Locati D, Allavena P, Colucci M, Semeraro N, et al. Generation of procoagulant activity by mononuclear phagocytes: a possible mechanism contributing to blood clotting activation within malignant tissues. Blood 1983;62:271-3.
10. Lando PA, Edgington TS. An innate host response to the neoplastic cell: syngeneic rat tumor cells can elict a rapid de novo lymphoid procoagulant response. J Immunol 1985;135:3587-95.
11. Miyauchi S, Moroyama T, Kyoizumi S, Asakawa J-I, Okamoto T, Takada K. Malignant tumor cell lines produce interleukiu-1-like factor. In Vitro Cell Dev Biol 1988;24:753-8.
12. Noguchi M, Sakai T, Kisiel W. Identification and partial purification of a novel tumor-derived protein that induces tissue factor on cultured human endothelial cells. Biochem Biophys Res Commun 1989; 160:222-7.
13. Dvorak HF, Nagy JA, Berse B, Brown LF, Yeo KT, Dvorak AM, et al. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann N Y Acad Sci 1992;667:101-11.
14. Clause M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535-45.
15. Dvorak HF. Abnormalities of hemostasis in malignant disease. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and thrombosis: basic principles and clinical practice. 3rd ed. Philadelphia: JB Lippincott, 1994:1238-54.
16. Rickles FR, Edwards RL. Leukocytes and tumor cells in thrombosis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and thrombosis: basic principles and clinical practice. 3rd ed. Philadelphia: JB Lippincott, 1994:1164-79.
17. Lindahl AK, Sandset PM, Abildgaard U. Indices of hypercoagulation in cancer as compared with those in acute inflammation and acute infarction. Haemostasis 1990;20:253-62.
18. 1.2 plasma concentrations in patients with gynecologic malignancies. Gynecol Oncol 1993; 49:373-6.
19. Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S. Evaluating prethrombotic state in lung cancer using molecular markers. Chest 1993;103:196-200.
20. Kemkes-Matthes B, Bleyl H. Factor IXi-antithrombin (IXiAT) and thrombin-antithrombin (TAT) complexes in lung cancer patients. Ann Hematol 1992;64:35-9.
21. Naschitz JE, Yeshurun D, Lev LM. Thromboembolism in cancer: changing trends. Cancer 1993;71:1384-90.
22. Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 1981;65:677-9.
23. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen: a study of 159 patients. Cancer 1984;54:1264-8.
24. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-7.
25. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-94.
26. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-9.
27. Nicolson GL, Custead SE. Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity. Cancer Res 1985;45:331-6.
28. Rogers JS II, Murgo AJ, Fontana JA, Raich PC. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 1988;6:276-81.
29. Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990; 65:885-9.
30. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency. Blood 1994;83:386-91.
31. Grignani G, Pacchiarini L, Pagliarino M. The possible role of blood platelets in tumour growth and dissemination. Haematologica 1986; 71:245-55.
32. Rosenthal DS, Murphy S. Thrombocytosis. In: Handin RI, Lux SE, Stossel TP, editors. Blood: principles and practice of hematology. Philadelphia: JB Lippincott, 1995:439-55.
33. Corbett G, Perry DJ. Significance of thrombocytosis [letter]. Lancet 1983;1:77.
34. Ratnoff OD. Hemostatic emergencies in malignancy. Semin Oncol 1989;16:561-71.
35. Rajan R, Gafni A, Levine M, Hirsh J, Gent M. Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation. J Clin Oncol 1995;13:42-46.
36. Bern MM, Lokich JJ, Wallach SR, Bothe A Jr., Benotti PN, Arkin CF, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized prospective trial. Ann Int Med 1990; 112:423-8.
37. Kakkar W, Howe CT, Nicolaides AN, Renney JTG, Clarke MB. Deep vein thrombosis of the leg: is there a 'high risk' group? Am J Surg 1970;120:527-30.
38. Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep leg vein thrombosis after major gynaecological surgery using labelled fibrinogen-phlebography and lung scanning. J Obstet Gynaecol Br Commonw 1974;81:311-6.
39. Rosenberg IL, Evans M, Pollock AV. Prophylaxis of postoperative leg vein thrombosis by low dose subcutaneous heparin or peroperative calf muscle stimulation: a controlled clinical trial. Br Med J 1975;1:649-51.
40. Sue-Ling HM, Johnston D, McMahon MJ, Philips PR, Davies JA. Preoperative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet 1986;1:1173-6.
41. Allan A, Williams JT, Bolton JP, Le Quesne LP. The use of graduated compression stockings in the prevention of postoperative deep vein thrombosis. Br J Surg 1983;70:172-4.
42. The Multicentre Trial Committee. Dihydroergotamine-heparin prophylaxis of postoperative deep vein thrombosis: a multicentre trial. JAMA 1984;251:2960-6.
43. Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge: an underestimated risk. Arch Surg 1992;127:310-3.
44. Hirsch DR, Lee TH, Morrison RB, Carlson W, Goldhaber SZ. Shortened hospitalization by means of adjusted-dose subcutaneous heparin for deep venous thrombosis. Am Heart J 1996;131:276-80.
45. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1995; 70:725-33.
46. Aderka D, Brown A, Zelikovski A, Pinkhas J. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer 1986;57:1846-9.
47. Monreal M, Salvador R, Soriano V, Sabria M. Cancer and deep venous thrombosis [letter]. Arch Intern Med 1988;148:485.
48. Monreal M, Lafoz E, Casals A, Inaraja L, Montserrat E, Callejas JM, et al. Occult cancer in patients with deep venous thrombosis: a systematic approach. Cancer 1991;67:541-5.
49. Prandoui P, Lensing AWA, Buller HR, Cogo A, Prins MH, Cattelan AM, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-33.
50. Comuz J, Pearson S, Creager MA, Goldman L. Initial evaluation for cancer in patients with symptomatic deep vein thrombosis [abstract]. J Invest Med 1995;43(Suppl 2):304A.